These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

966 related articles for article (PubMed ID: 18175316)

  • 1. Structure-function relationship of inhibitory Smads: Structural flexibility contributes to functional divergence.
    Hariharan R; Pillai MR
    Proteins; 2008 Jun; 71(4):1853-62. PubMed ID: 18175316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling and analysis of MH1 domain of Smads and their interaction with promoter DNA sequence motif.
    Makkar P; Metpally RP; Sangadala S; Reddy BV
    J Mol Graph Model; 2009 Apr; 27(7):803-12. PubMed ID: 19157940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crk-associated substrate lymphocyte type regulates transforming growth factor-beta signaling by inhibiting Smad6 and Smad7.
    Inamoto S; Iwata S; Inamoto T; Nomura S; Sasaki T; Urasaki Y; Hosono O; Kawasaki H; Tanaka H; Dang NH; Morimoto C
    Oncogene; 2007 Feb; 26(6):893-904. PubMed ID: 16909115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles for the MH2 domain of Smad7 in the specific inhibition of transforming growth factor-beta superfamily signaling.
    Mochizuki T; Miyazaki H; Hara T; Furuya T; Imamura T; Watabe T; Miyazono K
    J Biol Chem; 2004 Jul; 279(30):31568-74. PubMed ID: 15148321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling.
    Hanyu A; Ishidou Y; Ebisawa T; Shimanuki T; Imamura T; Miyazono K
    J Cell Biol; 2001 Dec; 155(6):1017-27. PubMed ID: 11739411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone morphogenetic protein activities are enhanced by 3',5'-cyclic adenosine monophosphate through suppression of Smad6 expression in osteoprogenitor cells.
    Sugama R; Koike T; Imai Y; Nomura-Furuwatari C; Takaoka K
    Bone; 2006 Feb; 38(2):206-14. PubMed ID: 16203197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of transforming growth factor-beta signaling.
    Zhu HJ; Burgess AW
    Mol Cell Biol Res Commun; 2001 Nov; 4(6):321-30. PubMed ID: 11703090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homology modeling of the DNA-binding domain of human Smad5: a molecular model for inhibitor design.
    Hariharan R; Pillai MR
    J Mol Graph Model; 2006 Jan; 24(4):271-7. PubMed ID: 16243555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.
    Kuang C; Chen Y
    Oncogene; 2004 Feb; 23(5):1021-9. PubMed ID: 14647410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation.
    Zhang S; Fei T; Zhang L; Zhang R; Chen F; Ning Y; Han Y; Feng XH; Meng A; Chen YG
    Mol Cell Biol; 2007 Jun; 27(12):4488-99. PubMed ID: 17438144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterisation of a second structurally unusual AR-Smad without an MH1 domain and a Smad4 orthologue from Echinococcus multilocularis.
    Zavala-Góngora R; Derrer B; Gelmedin V; Knaus P; Brehm K
    Int J Parasitol; 2008 Feb; 38(2):161-76. PubMed ID: 17845804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma.
    Liu X; Lee J; Cooley M; Bhogte E; Hartley S; Glick A
    Cancer Res; 2003 Nov; 63(22):7760-8. PubMed ID: 14633701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGF-beta superfamily, in esophageal squamous cell carcinoma.
    Osawa H; Nakajima M; Kato H; Fukuchi M; Kuwano H
    Anticancer Res; 2004; 24(6):3703-9. PubMed ID: 15736400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for inhibitory effects of Smad7 on TGF-β family signaling.
    Murayama K; Kato-Murayama M; Itoh Y; Miyazono K; Miyazawa K; Shirouzu M
    J Struct Biol; 2020 Dec; 212(3):107661. PubMed ID: 33166654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can't get no SMADisfaction: Smad proteins as positive and negative regulators of TGF-beta family signals.
    Christian JL; Nakayama T
    Bioessays; 1999 May; 21(5):382-90. PubMed ID: 10376010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localization of Smad6 and Smad7 in the rat kidney and their regulated expression in the anti-Thy-1 nephritis.
    Uchida K; Nitta K; Kobayashi H; Kawachi H; Shimizu F; Yumura W; Nihei H
    Mol Cell Biol Res Commun; 2000 Aug; 4(2):98-105. PubMed ID: 11170839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echinococcus multilocularis: molecular characterization of EmSmadE, a novel BR-Smad involved in TGF-β and BMP signaling.
    Epping K; Brehm K
    Exp Parasitol; 2011 Oct; 129(2):85-94. PubMed ID: 21802416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-gamma abrogates profibrogenic TGF-beta signaling in liver by targeting expression of inhibitory and receptor Smads.
    Weng H; Mertens PR; Gressner AM; Dooley S
    J Hepatol; 2007 Feb; 46(2):295-303. PubMed ID: 17125875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Delta intracellular domain mediates TGF-beta/Activin signaling through binding to Smads and has an important bi-directional function in the Notch-Delta signaling pathway.
    Hiratochi M; Nagase H; Kuramochi Y; Koh CS; Ohkawara T; Nakayama K
    Nucleic Acids Res; 2007; 35(3):912-22. PubMed ID: 17251195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles for lysine residues of the MH2 domain of Smad3 in transforming growth factor-beta signaling.
    Imoto S; Sugiyama K; Sekine Y; Matsuda T
    FEBS Lett; 2005 May; 579(13):2853-62. PubMed ID: 15907489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.